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Resolution of a Modified CDC Definition for Carbapenem Resistant Enterobacteriaceae (CRE)
Using a Rapid Multiplex, Cartridge-Based Molecular Assay for the Confirmation of Carbapenemase
Genes

Harshita Mehrotra1, Laura Favazza2, Brie Kezlarian3, Randal Fowler4, Nancy Hanson4, Robert Tibbetts5
1
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Background: CRE have emerged as a global threat due to their potential to cause invasive infections, often with high mortality rates and
are primarily healthcare, associated, with a potential for spread to community settings. The CDC updated its definition of CRE as resistant
to a carbapenem: MIC of ≥4 ug/ml for doripenem, meropenem, or imipenem, ≥2 ug/ml for ertapenem, OR documented to produce a
carbapenemase. CRE are resistant to carbapenems primarily through the expression of carbapenemase genes (CP-CRE) carried on
plasmids, which are easily transferrable hence the CDC recommendation to isolate patients with CP-CRE. However, production of
AmpC/ESBL β-lactamases with a decrease of outer membrane proteins (OMP) (non-CP-CRE) can also lead to a higher ertapenem MIC, of
which OMPs are not transferable but meet the CDC definition for CRE. The purpose of this study was to develop an algorithm to
differentiate CP-CRE from non-CP-CRE using carbapenem MIC and confirmation by a rapid molecular assay.
Design: Genetic and phenotypic testing was performed on 61 isolates of Enterobacteriaceae with MICs to ertapenem ranging from <0.25
ug/ml to >64 ug/ml using PCR to detect blaKPC, blaAmpC and blaESBL, and SDS-PAGE to determine OMP production. These data were used
to create an algorithm to define CRE in our lab using MIC, the presence of resistance genes and/or OMP production. 40 isolates, including
positive and negative controls, with known antibiotic susceptibilities were defined by this algorithm and confirmed by commercially available
FDA approved rapid multiplex PCR for carbapenemase genes.
Results: Using this algorithm, we observed 5 discordant PCR results giving us 85% concordance. However, we believe that 3 of these
were due to loss of plasmids by repeated freeze-thaw cycles and intend to reanalyze MICs to confirm this. On eliminating these 3 isolates,
we have 93% concordance.
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Conclusions: A combination of the CDC definition for CRE and lowered breakpoints to ertapenem led to overcalling non-CP-CRE as CPCRE may have resulted in inappropriate patient isolation, which is known to have negative patient outcomes and increase
costs. Implementation of a multiplex PCR to rule out carbapenemases in isolates with elevated ertapenem but susceptible meropenem
MICs resulted in a more sensitive and specific identification of CP-CRE.
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STAS Tumor Status is a Reproducible Prognosticator Among Practicing Pathologists
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Background: “Spread through airspace” (STAS) is defined as the spread of tumor cells into airspaces in the lung parenchyma adjacent to
and beyond the edge of the main tumor. It is a newly recognized pattern of invasion reported in adenocarcinoma and squamous cell lung
carcinoma . Higher STAS has been reported to be more commonly seen in patients with solid and micropapillary predominant invasive
adenocarcinoma, pleural and lymphovascular invasion, and tumor size of 10 mm or larger. Also, STAS has been considered to be an
important risk factor for locoregional and distant recurrence in small adenocarcinomas treated by limited resection. In this study, we aim to
evaluate if the observer (pathologists) is a determinant of the STAS tumor status.
Design: All primary lung cancer reports from January 1, 2018 to August 1, 2019 were reviewed. A total of 247 CAP Tumor Summaries
were completed by our group of 8 general surgical pathologists, two of whom with interest in pulmonary pathology (pathologists 2 and 4). In
addition to reporting variability among pathologists, we evaluated the relation between STAS and histologic type, tumor size and grade, and
type of resection (lobectomy and wedge resection). This analysis was performed using a multivariate regression analysis conducted in
SPSS® (version 22.0; Chicago, Illinois, USA).
Results: STAS, was reported in 128 CAP summaries (52%). Only 2 of the pathologists reported STAS in all cases (pathologists 2 and 4).
The rate of positivity for rare reporters, pathologists 3, 6 and 8 was higher (66.66%) than the frequent reporters, pathologists 2 and 4
(26%), suggesting that rare reporters evaluated STAS when it was present in selected cases. Overall, when comparing frequent reporters
(pathologists 2 and 4) with all the other pathologists (1, 3, 5, 6, 7, 8), the positivity rate is not significantly different (27.27% vs. 24.13%,
respectively). Growth pattern was the only variable showing a significant association with the presence or absence of STAS in multivariate
analysis (Figure 1 and Table 1).
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Conclusions: This fit regression multivariate model demonstrates that the presence or absence of STAS is more likely to be determined
by the variable growth pattern with no significant contribution of other variables. As expected for a parameter with high reproducibility, this
result affirms that the observer (pathologist) is not significantly influencing the likelihood of STAS to be positive or negative.
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